Drug Discovery & Molecular Design - software & AI news

Daily news on software, AI, and companies shaping drug discovery & molecular design.

Showing 229 results
A vial of biopharmaceutical agent on a lab bench

Jun 5, 2026

Sanofi Inks Five-Year Pact to License Owkin’s AI Scientist K Pro for Next-Gen Biopharma Agents

Sanofi has entered a five-year licensing agreement with Owkin to utilize its AI scientist, K Pro, aimed at advancing biopharmaceutical development.This collaboration highlights a growing trend among major pharmaceutical companies to integrate AI technologies into their workflows. Owkin's K Pro is designed to function as an intelligent assistant, streamlining complex tasks in drug research and development. The partnership will enhance Sanofi’s existing capabilities in agentic AI, allowing for mor
A test tube with a colorful liquid on a lab bench

Jun 5, 2026

Earendil: A Blueprint for a Multipolar Life Sciences Era

Earendil Labs' recent $787 million financing marks a pivotal moment in the evolution of life sciences, highlighting a new paradigm in AI-enabled drug discovery.This funding round, one of the largest in the sector, reflects a strategic convergence of geographic and operational strengths from various global players. Earendil, based in Delaware and Beijing, is poised to leverage European scientific expertise, American computational advancements, and China's rapid execution capabilities. This model
A glass vial with clear liquid on a lab bench in a biotechnology lab

Jun 4, 2026

Alnylam, Inceptive ink AI deal potentially worth $2B

Alnylam Pharmaceuticals has announced a significant collaboration with Inceptive Nucleics, aiming to leverage artificial intelligence (AI) for the accelerated discovery of RNA-based therapies. The initial phase of the partnership includes a $30 million investment, with potential total deal value reaching $2 billion contingent on meeting various milestones.This partnership is a key component of Alnylam's broader "Alnylam 2030" strategy, which focuses on expanding its pipeline of innovative therap
Minimalist illustration of a drug compound

Jun 4, 2026

Alnylam Enters $2 Billion Strategic AI Collaboration with Inceptive

Alnylam Pharmaceuticals has initiated a significant collaboration with Inceptive, aiming to leverage generative AI to enhance its RNA interference (RNAi) drug discovery efforts. This partnership is strategically aligned with Alnylam's objectives for its Alnylam 2030 pipeline expansion, focusing on accelerating the development of innovative RNAi therapeutics. Inceptive's AI platform is designed to identify complex biological patterns and apply them across various therapeutic contexts without the
A minimalist representation of a molecular structure in a dark color scheme.

Jun 4, 2026

Pfizer to Leverage Chai Discovery’s AI Platform

Pfizer has announced a strategic partnership with Chai Discovery to integrate advanced AI capabilities into its drug development processes.This collaboration will allow Pfizer to utilize Chai's AI platform, specifically the Chai-3 model and a customized version that incorporates Pfizer's proprietary data. The aim is to enhance Pfizer's drug discovery engine, streamlining the identification and development of new therapeutic molecules.Chai Discovery specializes in generative AI technology that ca
A drug compound on a laboratory notebook in a research lab

Jun 4, 2026

Meet Dalton, a new AI-powered drug discovery platform

DaltonTx has launched its AI-driven drug discovery platform, Dalton, aimed at streamlining the entire drug development process.The UK-based start-up DaltonTx has officially introduced its platform, Dalton, which is designed to optimize drug discovery from data analysis to molecular design and decision-making. This innovative platform aims to create a "continuous learning engine" that supports both small-molecule and biologic medicines. With a team comprising former scientists from AstraZeneca, E
A minimalist illustration of a chromosome and genome strand representing advancements in genomics research.

Jun 4, 2026

OpenAI GPT-Rosalind Update Brings Advanced AI Drug Discovery and Genomics Research Capabilities

OpenAI has unveiled a major update to its GPT-Rosalind model, enhancing its capabilities in drug discovery and genomics research.The June 3, 2026 announcement highlights advancements in the GPT-Rosalind series, which is tailored for life sciences research, particularly in drug discovery and genomics. This update integrates the sophisticated features of GPT 5.5, aiming to improve performance in critical areas such as medicinal chemistry and experimental biology. OpenAI emphasizes that progress in
An RNA molecule on a lab bench in a dimly lit laboratory setting.

Jun 4, 2026

AI Collaboration Puts Alnylam’s RNAi Pipeline Productivity In Focus

Alnylam Pharmaceuticals has entered a collaboration with Inceptive Nucleics to enhance RNA interference (RNAi) drug discovery through the application of generative AI models. This partnership aims to streamline the drug design process, potentially increasing the efficiency and speed of developing new therapeutics as part of Alnylam's broader strategy for 2030.The collaboration seeks to leverage Inceptive's expertise in AI to optimize RNAi drug design, thereby shortening the trial-and-error phase
A minimalist representation of a pill and a molecule symbolizing drug discovery.

Jun 3, 2026

Nxera Pharma: Obesity pipeline advances, commercial growth, and AI-driven discovery fuel strategic momentum

Nxera Pharma is making notable strides in its obesity and rare disease pipelines, showcasing advancements in novel oral small molecules and the potential for out-licensing key assets.The company's commercial growth is particularly evident in Japan, where they have achieved significant milestone income. This success is bolstered by the introduction of a new AI-driven drug discovery platform, which is integral to their strategy aimed at specialty and rare diseases.This momentum reflects Nxera's co
A biological data model on a lab table with research equipment in the background.

Jun 3, 2026

Ingenix raises €13m to scale AI drug development engine

Ingenix has successfully secured €13 million in funding to enhance its AI-driven drug development capabilities, building on a previous €9 million seed round. This investment aims to expand the company's Biological Reasoning Engine, a sophisticated AI tool designed to facilitate translational and clinical research decisions, while also increasing collaboration opportunities with pharmaceutical and biotech partners.Founded in 2023, Ingenix is pioneering an innovative approach known as Modality Fus
A test tube with a liquid sample on a lab countertop

Jun 3, 2026

Exclusive: Apoha, startup pioneering AI based on liquid 'wave form' data, debuts with $36 million

Apoha, a pioneering startup in AI-driven material science, has emerged from stealth with $36 million in funding to develop innovative substances based on unique liquid wave form data.The funding comprises a seed round from 2024 and a recent unlettered round, led by Singular, with support from other venture firms and a grant from Innovate UK. Apoha aims to leverage a novel type of data—wave forms generated by materials in liquid under external forces—to enhance the creation and modification of va
Flat illustration of a computer chip representing data analytics in drug development.

Jun 3, 2026

Evotec Appoints Rui Wang as Head of Global In Silico and AI

Evotec has appointed Rui Wang as the new Executive Vice President, Head of Global In Silico and AI, marking a significant step in enhancing its AI-driven research and development capabilities.With over two decades of experience in the pharmaceutical and biotechnology sectors, Wang will lead efforts to integrate data analytics and AI throughout Evotec's R&D processes. His previous role at AstraZeneca involved overseeing data and AI initiatives, equipping him with the expertise to drive innovation